Elisabeth Livingstone

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

David Liu, Bastian Schilling, Derek Liu et al. · Nature Medicine · 2019 · 1K citations · Full text

Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma

Lisa Zimmer, Julia Vaübel, Peter Mohr et al. · PLoS ONE · 2015 · 286 citations · Full text

TERT Promoter Mutation Status as an Independent Prognostic Factor in Cutaneous Melanoma

Klaus Griewank, Rajmohan Murali, Joan Anton Puig‐Butillé et al. · JNCI Journal of the National Cancer Institute · 2014 · 251 citations · Full text

Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial

Lisa Zimmer, Elisabeth Livingstone, Jessica C. Hassel et al. · The Lancet · 2020 · 238 citations

Surgical Oncology, Oncology, Melanoma +6

Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective <i>BRAF</i> Inhibition

Lisa Zimmer, Uwe Hillen, Elisabeth Livingstone et al. · Journal of Clinical Oncology · 2012 · 224 citations · Full text